Retroperitoneal SarcomaPhase 1/2NCT01659203
Preoperative Proton or Photon (IMRT) Radiation
Proton or Photon RT for Retroperitoneal Sarcomas
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
What the film says
Rhabdomyosarcoma is the most common soft tissue cancer in children. Low-risk disease is usually cured; when it comes back, fewer than one in five survive five years.
The idea: every rhabdomyosarcoma cell carries the same surface receptor, so aim engineered T cells at it.
That receptor is FGFR4. NCI researchers showed it sits on essentially all rhabdomyosarcomas and drives the most aggressive form, so it need not even be tested. A patient's T cells are collected, given a receptor for FGFR4, and returned in one infusion after four days of chemotherapy clears space.
A first dose-finding study, ages three to thirty-nine, after at least two prior treatments failed. Srivandana Akshintala leads it at the NIH Clinical Center. Public record; not medical advice.
Sources behind this film
Most common pediatric soft tissue sarcoma; recurrent 5-year survival 17%; FGFR4 universally expressed in RMS; PAX3-FOXO1 super-enhancer drives it in FP-RMS; FGFR4 confirmation not required; Apheresis; Flu days −5 to −2, Cy days −4 to −2; infusion day 0 (+1 more lines)
The drug
Single intravenous (IV) infusion on Day 0
30 mg/m2 per day IV on days -5, -4, -3, -2
Background: * Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an annual incidence of 4.5 cases per 1 million children and is the third most prevalent extracranial solid tumor of childhood after neuroblastoma and Wilms tumor. * RMS is divided into two main subtypes, fusion negative (FN-RMS) driven by RAS pathway mutations, and fusion positive rhabdomyosarcoma (FP-RMS) driven by PAX3/PAX7-FOXO1 fusion genes.
The study
Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T cells, a type of immune cell; then they will change the T cells so they are better able to target the FGFR4 protein and attack RMS tumor cells.
The modified T cells are chimeric antigen receptor (CAR) T cells. The treatment in this study is called FGFR4-CAR T cells. Objective: To test FGFR4-CAR T cells in children and young adults with RMS. Eligibility: People aged 3 to 39 years with RMS. The RMS must have failed to respond or returned after at least 2 rounds of standard treatment. Design: Participants will be screened. They will have physical exam, imaging scans, blood tests, and tests of their heart.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.